SCHEMBL13118289

SCHEMBL13118289

CCCN(CC)CC(CC)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CHRM1 P11229 2/20 0.41
▸ CHRM3 P20309 2/20 0.41
▸ AKR1A1 P14550 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ SLC1A2 P43004 4/20 0.39
▸ SLC1A1 P43005 4/20 0.39
▸ SLC1A3 P43003 3/20 0.39
▸ CA12 O43570 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ GRIK1 P39086 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10567426 0.87 CA2 (0.46) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL11286650 0.83 CA2 (0.50) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL13118292 0.81 CA2 (0.32) CA2MAPK1CA12CA9
SCHEMBL28475581 0.76 FOLH1 (0.42) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL28233378 0.76 SLC1A3 (0.44) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL29624642 0.75 CA2 (0.54) CA2MAPK1CHRM1CHRM3AKR1A1
2-Ethylhexanoic Acid SCHEMBL5874518 0.74 CA2 (0.77) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL10800695 0.72 CA2 (0.45) CA2MAPK1CHRM1CHRM3AKR1A1
SCHEMBL8587841 0.72 CA2 (0.61) CA2MAPK1CHRM1CHRM3AKR1A1
2-Ethylhexanoic Acid SCHEMBL5874905 0.72 CA2 (0.80) CA2MAPK1CHRM1CHRM3AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 — — US disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261714-A1 INHIBITORS OF HIV REPLICATION RTF2, POLR1A, REV1 CA2 4448/4885MAPK1 1428/4885CHRM1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback